BRAF and neoplasm: Although it has been shown that the MAPK signalling cascade can increase VEGF expression and that BRAF mutation might also modulate tumour response to anti-angiogenic treatments,35 the value of bevacizumab in BRAF-mt patients has not yet been clinically demonstrated.